DE60042283D1 - Kombination eines abl-, pdgf-rezeptor- und/oder kit rezeptor-tyrosin kinase inhibitors mit einer organischen substanz, die an alpha1-acidisches glycoprotein bindet - Google Patents
Kombination eines abl-, pdgf-rezeptor- und/oder kit rezeptor-tyrosin kinase inhibitors mit einer organischen substanz, die an alpha1-acidisches glycoprotein bindetInfo
- Publication number
- DE60042283D1 DE60042283D1 DE60042283T DE60042283T DE60042283D1 DE 60042283 D1 DE60042283 D1 DE 60042283D1 DE 60042283 T DE60042283 T DE 60042283T DE 60042283 T DE60042283 T DE 60042283T DE 60042283 D1 DE60042283 D1 DE 60042283D1
- Authority
- DE
- Germany
- Prior art keywords
- abl
- binds
- alpha
- combination
- tyrosine kinase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT1999MI002711A ITMI992711A1 (it) | 1999-12-27 | 1999-12-27 | Composti organici |
PCT/EP2000/013161 WO2001047507A2 (en) | 1999-12-27 | 2000-12-22 | Combinations of receptor tyrosine kinase inhibitor with an a1-acidic glycoprotein binding compound |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60042283D1 true DE60042283D1 (de) | 2009-07-09 |
Family
ID=11384195
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60042283T Expired - Lifetime DE60042283D1 (de) | 1999-12-27 | 2000-12-22 | Kombination eines abl-, pdgf-rezeptor- und/oder kit rezeptor-tyrosin kinase inhibitors mit einer organischen substanz, die an alpha1-acidisches glycoprotein bindet |
Country Status (18)
Country | Link |
---|---|
US (2) | US20030125343A1 (de) |
EP (1) | EP1250140B1 (de) |
JP (1) | JP2003523325A (de) |
CN (1) | CN1304005C (de) |
AR (1) | AR030179A1 (de) |
AT (1) | ATE432069T1 (de) |
AU (1) | AU2171901A (de) |
BR (1) | BR0016817A (de) |
CA (1) | CA2394944A1 (de) |
CO (1) | CO5271710A1 (de) |
DE (1) | DE60042283D1 (de) |
ES (1) | ES2326307T3 (de) |
HK (1) | HK1050993A1 (de) |
IT (1) | ITMI992711A1 (de) |
PE (1) | PE20010991A1 (de) |
PT (1) | PT1250140E (de) |
TW (1) | TWI246917B (de) |
WO (1) | WO2001047507A2 (de) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60130017T2 (de) * | 2000-11-22 | 2008-05-15 | Novartis Ag | Kombination enthaltend ein mittel zur verminderung von vegf-aktivität und ein mittel zur verminderung von egf-aktivität |
US6878697B2 (en) | 2001-06-21 | 2005-04-12 | Ariad Pharmaceuticals, Inc. | Phenylamino-pyrimidines and uses thereof |
GB0119249D0 (en) | 2001-08-07 | 2001-10-03 | Novartis Ag | Organic compounds |
US7323469B2 (en) | 2001-08-07 | 2008-01-29 | Novartis Ag | 7H-pyrrolo[2,3-d]pyrimidine derivatives |
DE10141650C1 (de) | 2001-08-24 | 2002-11-28 | Lohmann Therapie Syst Lts | Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen |
MXPA04003878A (es) * | 2001-10-25 | 2004-07-08 | Novartis Ag | Combinaciones que comprenden un inhibidor selectivo de cicloxigenasa-2. |
GB0201508D0 (en) | 2002-01-23 | 2002-03-13 | Novartis Ag | Organic compounds |
US20060128720A1 (en) * | 2002-03-21 | 2006-06-15 | Kufe Donald W | Inhibition of cell death responses induced by oxidative stress |
AU2007201830C1 (en) * | 2002-04-23 | 2017-09-07 | Novartis Pharma Ag | High drug load tablet |
GB0209265D0 (en) * | 2002-04-23 | 2002-06-05 | Novartis Ag | Organic compounds |
US20060052387A1 (en) * | 2002-06-26 | 2006-03-09 | Marsh Clay B | Organic compounds |
BR0312821A (pt) * | 2002-07-24 | 2005-04-19 | Akira Ohtsuru | 4-(4-metil-piperazin-1-il-metil)-n-[(4-metil-3-(4-piridin-3-i l)-pirimidin-2-il-amino)-fenil]-benzamida para tratar câncer anaplásico da tireóide |
EP1542989B1 (de) * | 2002-07-31 | 2007-04-18 | Critical Outcome Technologies, Inc. | Protein tyrosin kinase inhibitoren |
GB0222514D0 (en) | 2002-09-27 | 2002-11-06 | Novartis Ag | Organic compounds |
ATE380810T1 (de) * | 2002-10-09 | 2007-12-15 | Critical Outcome Technologies | Protein-tyrosine-kinase-inhibitoren |
AU2003268185A1 (en) * | 2003-08-25 | 2005-04-11 | Dana-Farber Cancer Institute Inc. | Method of treating mixed lineage leukemia gene-rearranged acute lymphoblastic leukemias |
CN100467064C (zh) * | 2003-09-19 | 2009-03-11 | 诺瓦提斯公司 | 伊马替尼和米哚妥林在制备治疗胃肠道基质肿瘤药物中的应用 |
TW200517114A (en) * | 2003-10-15 | 2005-06-01 | Combinatorx Inc | Methods and reagents for the treatment of immunoinflammatory disorders |
PL1720853T3 (pl) † | 2004-02-11 | 2016-06-30 | Natco Pharma Ltd | Nowa odmiana polimorficzna metanosulfonianu imatynibu i sposób jej otrzymywania |
US7358250B2 (en) | 2004-06-29 | 2008-04-15 | Amgen Inc. | Pyrrolo[2,3-d]pyrimidines that modulate ACK1 activity |
JP2008508358A (ja) * | 2004-08-02 | 2008-03-21 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | アリール−アミノ置換ピロロピリミジンマルチキナーゼ阻害化合物 |
ATE519759T1 (de) | 2004-12-30 | 2011-08-15 | Exelixis Inc | Pyrimidinderivate als kinasemodulatoren und anwendungsverfahren |
US20070059359A1 (en) * | 2005-06-07 | 2007-03-15 | Thomas Backensfeld | Immediate-release and high-drug-load pharmaceutical formulations of non-micronised (4-chlorophenyl)[4-(4-pyridylmethyl)phthalazin-1-yl] and salts thereof |
US20060275365A1 (en) * | 2005-06-07 | 2006-12-07 | Thomas Backensfeld | Immediate-release and high-drug-load pharmaceutical formulations of micronised (4-chlorophenyl) [4-(4-pyridylmethyl)phthalazin-1-yl] and salts thereof |
US20080214445A1 (en) * | 2005-06-23 | 2008-09-04 | Sebastien Bihorel | Method of Treating a Solid Tumor Disease Comprising Administering a Combination Comprising Imatinib and an Inhibitor of an Efflux Pump Active at the Blood Brain Barrier or Demethyl Imatinib |
RU2441869C2 (ru) * | 2005-12-21 | 2012-02-10 | Эбботт Лэборетриз | Противовирусные соединения |
EP1971611B1 (de) | 2005-12-21 | 2012-10-10 | Abbott Laboratories | Antivirale verbindungen |
ATE475660T1 (de) | 2005-12-21 | 2010-08-15 | Abbott Lab | Antivirale verbindungen |
ES2458291T3 (es) * | 2006-04-20 | 2014-04-30 | Janssen Pharmaceutica Nv | Derivados de amidas aromáticas como inhibidores de la cinasa C-KIT |
AU2007269540B2 (en) * | 2006-07-05 | 2013-06-27 | Exelixis, Inc. | Methods of using IGF1R and Abl kinase modulators |
US8236950B2 (en) | 2006-12-20 | 2012-08-07 | Abbott Laboratories | Anti-viral compounds |
EP2121681B1 (de) | 2007-01-11 | 2015-04-15 | Critical Outcome Technologies, Inc. | Verbindungen und verfahren zur behandlung von krebs |
US20080248548A1 (en) * | 2007-04-09 | 2008-10-09 | Flynn Daniel L | Modulation of protein functionalities |
WO2009042803A1 (en) * | 2007-09-25 | 2009-04-02 | Teva Pharmaceutical Industries Ltd. | Imatinib compositions |
WO2009079797A1 (en) * | 2007-12-26 | 2009-07-02 | Critical Outcome Technologies, Inc. | Compounds and method for treatment of cancer |
EA201070841A1 (ru) | 2008-01-11 | 2011-02-28 | Натко Фарма Лимитед | НОВЫЕ ПИРАЗОЛО[3,4-d]ПИРИМИДИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ПРОТИВОРАКОВЫХ ЛЕКАРСТВЕННЫХ СРЕДСТВ |
US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
KR101956261B1 (ko) | 2008-05-21 | 2019-03-08 | 어리어드 파마슈티칼스, 인코포레이티드 | 키나아제 억제제로서 포스포러스 유도체 |
EP2318406B1 (de) | 2008-07-17 | 2016-01-27 | Critical Outcome Technologies, Inc. | Thiosemicarbazonhemmerverbindungen und krebsbehandlungsverfahren |
CA2744563A1 (en) | 2008-12-12 | 2010-06-17 | Ariad Pharmaceuticals, Inc. | Azaindole derivatives as kinase inhibitors |
ITRM20090578A1 (it) * | 2009-11-10 | 2011-05-11 | Noi Per Voi Onlus | Nuove composizioni per il trattamento di leucemie chemioresistenti e/o di leucemie potenzialmente chemioresistenti. |
EP2552915B1 (de) | 2010-04-01 | 2017-07-19 | Critical Outcome Technologies Inc. | Verbindungen zur behandlung von hiv |
AR083797A1 (es) | 2010-11-10 | 2013-03-20 | Novartis Ag | Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos |
TR201010618A2 (tr) * | 2010-12-20 | 2012-07-23 | Bi̇lgi̇ç Mahmut | İmatinib içeren bir oral dozaj formu ve bu oral dozaj formunun üretimi |
PL394169A1 (pl) | 2011-03-09 | 2012-09-10 | Adamed Spółka Z Ograniczoną Odpowiedzialnością | Kompozycja farmaceutyczna metanosulfonianu imatinibu do napełniania jednostkowych postaci dawkowania oraz sposób jej wytwarzania |
JP5999177B2 (ja) | 2011-05-04 | 2016-09-28 | アリアド・ファーマシューティカルズ・インコーポレイテッド | Egfr発動性がんの細胞増殖阻害用化合物 |
EP2817030A1 (de) | 2012-02-21 | 2014-12-31 | Ranbaxy Laboratories Limited | Stabile dosierungsformen von imatinib-mesylat |
WO2013169401A1 (en) | 2012-05-05 | 2013-11-14 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in egfr-driven cancers |
US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
WO2017078647A1 (en) | 2015-11-05 | 2017-05-11 | Koçak Farma Ilaç Ve Kimya Sanayi Anonim Şirketi | Pharmaceutical compositions of imatinib |
EP3257499A1 (de) | 2016-06-17 | 2017-12-20 | Vipharm S.A. | Verfahren zur herstellung von imatinib methansulfonat kapseln |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5587459A (en) * | 1994-08-19 | 1996-12-24 | Regents Of The University Of Minnesota | Immunoconjugates comprising tyrosine kinase inhibitors |
US5750493A (en) * | 1995-08-30 | 1998-05-12 | Raymond F. Schinazi | Method to improve the biological and antiviral activity of protease inhibitors |
US20030069174A1 (en) * | 1997-03-10 | 2003-04-10 | Ludwig Pichler | Use of human alpha1-acid glycoprotein for producing a pharmaceutical preparation |
CO4940418A1 (es) * | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
WO2001004125A1 (fr) * | 1999-07-13 | 2001-01-18 | Kyowa Hakko Kogyo Co., Ltd. | Derives de staurosporine |
DZ3248A1 (fr) * | 1999-12-10 | 2001-06-14 | Pfizer Prod Inc | Composés à base de pyrrolo[2,3-d]pyrimidine |
-
1999
- 1999-12-27 IT IT1999MI002711A patent/ITMI992711A1/it unknown
-
2000
- 2000-12-08 TW TW089126229A patent/TWI246917B/zh active
- 2000-12-22 AU AU21719/01A patent/AU2171901A/en not_active Abandoned
- 2000-12-22 CO CO00097404A patent/CO5271710A1/es not_active Application Discontinuation
- 2000-12-22 AT AT00985244T patent/ATE432069T1/de active
- 2000-12-22 PE PE2000001393A patent/PE20010991A1/es not_active Application Discontinuation
- 2000-12-22 BR BR0016817-3A patent/BR0016817A/pt not_active Application Discontinuation
- 2000-12-22 CA CA002394944A patent/CA2394944A1/en not_active Abandoned
- 2000-12-22 JP JP2001548102A patent/JP2003523325A/ja active Pending
- 2000-12-22 AR ARP000106887A patent/AR030179A1/es not_active Application Discontinuation
- 2000-12-22 PT PT00985244T patent/PT1250140E/pt unknown
- 2000-12-22 EP EP00985244A patent/EP1250140B1/de not_active Expired - Lifetime
- 2000-12-22 DE DE60042283T patent/DE60042283D1/de not_active Expired - Lifetime
- 2000-12-22 US US10/169,035 patent/US20030125343A1/en not_active Abandoned
- 2000-12-22 CN CNB008178976A patent/CN1304005C/zh not_active Expired - Fee Related
- 2000-12-22 ES ES00985244T patent/ES2326307T3/es not_active Expired - Lifetime
- 2000-12-22 WO PCT/EP2000/013161 patent/WO2001047507A2/en active Search and Examination
-
2003
- 2003-03-12 HK HK03101801.4A patent/HK1050993A1/zh unknown
-
2009
- 2009-03-04 US US12/397,374 patent/US20090221519A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1250140A2 (de) | 2002-10-23 |
JP2003523325A (ja) | 2003-08-05 |
ITMI992711A0 (it) | 1999-12-27 |
WO2001047507A3 (en) | 2002-04-04 |
CN1414858A (zh) | 2003-04-30 |
US20030125343A1 (en) | 2003-07-03 |
CO5271710A1 (es) | 2003-04-30 |
CN1304005C (zh) | 2007-03-14 |
ATE432069T1 (de) | 2009-06-15 |
EP1250140B1 (de) | 2009-05-27 |
ES2326307T3 (es) | 2009-10-07 |
AR030179A1 (es) | 2003-08-13 |
CA2394944A1 (en) | 2001-07-05 |
BR0016817A (pt) | 2002-10-01 |
AU2171901A (en) | 2001-07-09 |
US20090221519A1 (en) | 2009-09-03 |
TWI246917B (en) | 2006-01-11 |
PE20010991A1 (es) | 2001-10-23 |
ITMI992711A1 (it) | 2001-06-27 |
HK1050993A1 (zh) | 2003-07-18 |
PT1250140E (pt) | 2009-08-24 |
WO2001047507A2 (en) | 2001-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60042283D1 (de) | Kombination eines abl-, pdgf-rezeptor- und/oder kit rezeptor-tyrosin kinase inhibitors mit einer organischen substanz, die an alpha1-acidisches glycoprotein bindet | |
NO20000487D0 (no) | Substituerte quinazolinderivater og anvendelse derav som tyrosin kinase inhibitorer | |
NO20021820L (no) | Tyrosinkinaseinhibitorer | |
CY2014034I2 (el) | Υποκατεστημενες 3-κυανοκινολινες ως αναστολεις κινασων πρωτεϊνης τυροσινης | |
ATE318603T1 (de) | Pyrrolotriazin kinasehemmer | |
NO20014970D0 (no) | Cyklisk protein-tyrosin-kinase-inhibitor | |
NO20011575D0 (no) | Substituerte 3-cyanokinoliner som proteintyrosin-kinase- inhibitorer | |
DZ3186A1 (fr) | Ptéridinones utilisées comme inhibiteurs de kinase. | |
NO20026010D0 (no) | Substituerte quinazolinderivater og deres anvendelse som inhibitorer | |
NO20053356D0 (no) | Aminindazolderivater og anvendelse derav som kinaseinhibitorer. | |
EE200200576A (et) | Oksasooli derivaadid ja nende kasutamine türosiini kinaasi inhibiitoritena | |
ATE395346T1 (de) | Chinazolinderivate als tyrosinkinaseinhibitoren | |
ATE430149T1 (de) | Heterocyclen substituierte imidazopyrazine als protein- tyrosin-kinase-inhibitoren | |
ATE446093T1 (de) | Substituierte chinazolin-derivate als aurora- kinase inhibitoren | |
DE122008000002I1 (de) | Pyrrol substituierte indolin-2-on protein kinase inhibitoren | |
ATE537843T1 (de) | Neue kinase-hemmer | |
NO20032848L (no) | Substituerte triazoldiaminderivater som kinaseinhibitorer | |
NO20011356D0 (no) | Pyrrolopyrimidiner som proteinkinase-inhibitorer | |
DE60101323D1 (de) | Tricyclische proteinkinasehemmer | |
IS2568B (is) | Kínasólínafleiður sem SRC týrósínkínasatálmar | |
NO20015062D0 (no) | Substituerte 3-cyano-[1.7],[1.5]og[1.8]-naftyridin- inhibitorer for tyrosin-kinaser | |
ITBO990293A0 (it) | Metodo di controllo di banconote . | |
FI20011722A0 (fi) | Menetelmä tärkkelyksen modifioimiseksi, tärkkelys ja sen käyttö | |
DK1690853T3 (da) | Omega-carboxyaryl-substituerede diphenylurinstoffer til anvendelse som raf-kinaseinhibitorer | |
ES1045196Y (es) | Torno para toldos y similares. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8328 | Change in the person/name/address of the agent |
Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN |